Abstract
Background Japan is fast becoming an extremely aged society and older adults are known to be at risk of severe COVID-19. However, the impact of risk factors specific to this population for severe COVID-19 caused by the Omicron variant of concern (VOC) are not yet clear.
Methods We performed an exploratory analysis using logistic regression to identify risk factors for severe COVID-19 illness among 4,868 older adults with a positive SARS-CoV-2 test result who were admitted to a healthcare facility between 1 January 2022 and 16 May 2022. We then conducted one-to-one propensity score (PS) matching for three factors—dementia, admission from a long-term care facility, and poor physical activity status—and used Fisher’s exact test to compare the proportion of severe COVID-19 cases in the matched data. We also estimated the average treatment effect on treated (ATT) in each PS matching analysis.
Results Of the 4,868 cases analyzed, 1,380 were severe. Logistic regression analysis showed that age, male sex, cardiovascular disease, cerebrovascular disease, chronic lung disease, renal failure and/or dialysis, physician-diagnosed obesity, admission from a long-term care facility, and poor physical activity status were risk factors for severe disease. Vaccination and dementia were identified as factors associated with non-severe illness. The ATT for dementia, admission from a long-term care facility, and poor physical activity status was −0.04 (95% confidence interval −0.07, −0.01), 0.09 (0.06, 0.12), and 0.17 (0.14, 0.19), respectively.
Conclusions Our results suggest that poor physical activity status and living in a long-term care facility have a substantial impact on the risk of severe COVID-19 caused by the Omicron VOC, while dementia might be associated with non-severe illness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Health and Labour Sciences Research Grant, Research on Emerging and Re-emerging Infectious Diseases and Immunization (grant number 19HA1003) and JSPS KAKENHI (grant number 20K10546).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study data were provided by Research Electronic Data Capture, a secure, Web-based data capture application hosted at the JCRAC Data Center of the National Center for Global Health and Medicine. The opt-out recruitment method was applied, and informed consents for individuals were waived, as approved by the National Center for Global Health and Medicine Ethics Review Board. Information about the entire research is available through the COVID-19 Registry Japan website (https://covid-registry.ncgm.go.jp/). This study was approved by the National Center for Global Health and Medicine Ethics Review Board (approval number: NCGM-G-003494-0).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data supporting the findings of this study are not publicly available due to the privacy of research participants and sites but are available upon reasonable request. Data on an individual level are shared with limitations to participating healthcare facilities through application to the REBIND project.
